Science & Enterprise subscription

Follow us on Twitter

  • A company using image analysis and deep learning to discover therapies for diseases often considered difficult to t… https://t.co/rnoQVhLISa
    about 43 mins ago
  • New post on Science and Enterprise: A.I. Discovery Company Raises $123M in Venture Funds https://t.co/2gXLZgLu0f #Science #Business
    about 46 mins ago
  • A clinical trial is underway assessing a drug approved for a rare inherited disease as a treatment for people hospi… https://t.co/Jyaa0PlA4A
    about 7 hours ago
  • New post on Science and Enterprise: Trial Testing Rare Disease Drug for Covid-19 Pneumonia https://t.co/2hAsoiN16x #Science #Business
    about 7 hours ago
  • Discoveries in a university lab that enable detection of Covid-19 infections from a person's breath are being licen… https://t.co/DgmvR2EcTr
    about 23 hours ago

Please share Science & Enterprise

FDA Clears Sanofi Four-Strain Flu Vaccine for Adults, Kids

Inspecting vaccine vials (Sanofi Pasteur)

Inspecting vaccine vials (Sanofi Pasteur)

Sanofi Pasteur, the vaccine division of the global pharmaceutical company Sanofi, says the Food and Drug Administration cleared for sale in the U.S. its Fluzone Quadrivalent vaccine that covers four influenza strains. The FDA action, says the company, will make the vaccine available for infants, adolescents, and adults.

The Centers for Disease Control and Prevention (CDC) recommends annual flu vaccinations for everyone six months and older. In the last flu season, from October 2012 through April 2013, CDC reported 12,343 hospitalizations from flu, or 44.3 hospitalizations per 100,000 people in the U.S.

The FDA action is an approval of Sanofi Pasteur’s biologics license application for the product. Until this year, most seasonal flu vaccines were trivalent, containing inactive viruses of the three influenza strains most likely faced in a particular flu season. The vaccines covered two A and one B type viruses

Starting this year, quadrivalent vaccines, covering two strains each of A and B type flu viruses are being made available. The addition of another B strain is needed, says Sanofi Pasteur, because of more than one B type viruses in circulation, which made it difficult for public health authorities to plan for an effective vaccine formulation for the upcoming season.

The company says its quadrivalent vaccine will be available in the U.S. for the 2013-2014 flu season, in prefilled syringes or single-dose vials for intramuscular administration. The CDC lists eleven vaccine products available for the 2013-2014 season, including two other quadrivalent vaccines by GlaxoSmithKline and MedImmune.

Read more:

Hat tip: FirstWord Pharma

*     *     *

Comments are closed.